Editorial

Polypharmacy in the Elderly: Time to Take Action and a Persona Perspective

DOI https://doi.org/10.70302/jpsim.v2i4.2163
Received: 09 Sep 2021 Accepted: 30 Sep 2021 Published Online: 14 Dec 2021

Abstract

How to Cite This Article

Jamil MQ, Mir FA. Polypharmacy in the Elderly: Time to Take Action and a Persona Perspective. J Pak Soc Intern Med. 2021;2(4):281–283. doi:10.70302/jpsim.v2i4.2163

⭳ Download PDF

Conflict of Interest

All authors declare no competing interests.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

No specific funding was received for this research.

Funder information follows the Crossref Funder Registry standard.

References

  1. World Health Organization. Medication safety in polypharmacy: technical report. [updated 2019, cited 2021] Available from: [https://www.who.int/publications/i/item/medication-safety-in-polypharmacy-technical-report]
  2. Department of health and social care, UK. National overprescribing report: Independent Report. [Updated 2021, cited 2021]Available from: [https://www.gov.uk/government/publications/national-overprescribing-review-report]
  3. Ahmed B, Nanji K, Mujeeb R, Patel MJ. Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: a prospective cohort study. PLoS One. 2014;9(11):e112133.
  4. Sarwar MR, Iftikhar S, Sarfraz M. Influence of Education Level of Older Patients on Polypharmacy, Potentially Inappropriate Medications Listed in Beer's Criteria, and Unplanned Hospitalization: A Cross-Sectional Study in Lahore, Pakistan. Medicina (Kaunas). 2018;54(4):57.
  5. Mazhar F, Akram S, Malhi SM, Haider N. A prevalence study of potentially inappropriate medications use in hospitalized Pakistani elderly. Aging Clin Exp Res. 2018;30(1):53-60.
  6. Das N, Khan AN, Badini ZA, Baloch H, Parkash J. Prescribing practices of consultants at Karachi, Pakistan. J Pak Med Assoc. 2001;51(2):74-7.
  7. Butool I, Nazir S, Afridi M, Shah SM. Evaluation and assessment of prescribing patterns in elderly patients using two explicit criteria based screening tools: (The PRISCUS list and STOPP/START criteria). Pak J Med Sci. 2018;34(6):1357-62.
  8. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57-65.
  9. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc. 2017;57(6):729-38.
  10. British National Formulary. [Updated 2021, Cited 2021]. Available from: [https://bnf.org]
  11. Molokhia M, Majeed A. Current and future perspectives on the management of polypharmacy. BMC Fam Pract. 2017;18(1):70.
  12. Siddiqui A, Siddiqui AS, Jawaid M, Zaman KA. Physician's Perception Versus Patient's Actual Incidence of Drug Non-adherence in Chronic Illnesses. Cureus. 201;9(11):e1893.
  13. Prescribing Safety Assessments. [Updated 2021, Cited 2021]. Available from: [https://prescribingsafetyassessment.ac.uk/]
  14. Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, Bonner C, Doust J, Colvin J, Heaney A, Turner R, McCaffery K. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. © 2021 Journal of Pakistan Society of Internal Medicine.